Barclays Lowers PT on Kenvue (KVUE) to $17 From $20, Keeps an Equal Weight Rating

Kenvue Inc. (NYSE:KVUE) is one of the best most oversold large cap stocks so far in 2025. On October 1, Barclays lowered the firm’s price target on Kenvue Inc. (NYSE:KVUE) to $17 from $20 while keeping an Equal Weight rating on the shares.

Kenvue’s (KVUE) Long-Term Value Creation and its Place in NYSE Dividend Stocks

The firm told investors that it adjusted its models to reflect “muted and decelerating” growth in certain parts of the personal care domain since the Q2 reports.

Kenvue Inc. (NYSE:KVUE) is a consumer health company that operates through three segments: Skin Health and Beauty, Self Care, and Essential Health.

Its Skin Health and Beauty segment offers hair care, body care, face care, and other product categories. The company’s global footprint spans more than 165 countries across its four regions.

While we acknowledge the potential of KVUE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KVUE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.